Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. SRNE Peers
See (SRNE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRNE | $0.00 | -77.55% | 1.2M | N/A | -$1.10 | N/A |
| VRTX | $443.54 | +0.61% | 113.9B | -115.51 | -$3.84 | N/A |
| REGN | $511.92 | +0.43% | 54.3B | 13.01 | $39.35 | +0.34% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $313.25 | +1.15% | 40.8B | -149.88 | -$2.09 | N/A |
| ARGX | $540.76 | -0.26% | 33B | 32.95 | $16.41 | N/A |
| BNTX | $103.05 | -3.27% | 24.8B | -28.16 | -$3.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.40 | +1.55% | 19.9B | 14.45 | $2.45 | +2.43% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
SRNE vs VRTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, VRTX has a market cap of 113.9B. Regarding current trading prices, SRNE is priced at $0.00, while VRTX trades at $443.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -115.51. In terms of profitability, SRNE's ROE is -19.05%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SRNE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs REGN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, REGN has a market cap of 54.3B. Regarding current trading prices, SRNE is priced at $0.00, while REGN trades at $511.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 13.01. In terms of profitability, SRNE's ROE is -19.05%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SRNE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs SGEN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRNE is priced at $0.00, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRNE's ROE is -19.05%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SRNE is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ALNY Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ALNY has a market cap of 40.8B. Regarding current trading prices, SRNE is priced at $0.00, while ALNY trades at $313.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -149.88. In terms of profitability, SRNE's ROE is -19.05%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SRNE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ARGX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ARGX has a market cap of 33B. Regarding current trading prices, SRNE is priced at $0.00, while ARGX trades at $540.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 32.95. In terms of profitability, SRNE's ROE is -19.05%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, SRNE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BNTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, SRNE is priced at $0.00, while BNTX trades at $103.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -28.16. In terms of profitability, SRNE's ROE is -19.05%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SRNE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BGNE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRNE is priced at $0.00, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRNE's ROE is -19.05%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SRNE is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RPRX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RPRX has a market cap of 19.9B. Regarding current trading prices, SRNE is priced at $0.00, while RPRX trades at $35.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 14.45. In terms of profitability, SRNE's ROE is -19.05%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SRNE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs DNA-WT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRNE is priced at $0.00, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRNE's ROE is -19.05%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SRNE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs SMMT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, SMMT has a market cap of 15.1B. Regarding current trading prices, SRNE is priced at $0.00, while SMMT trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -59.97. In terms of profitability, SRNE's ROE is -19.05%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SRNE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs INCY Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, INCY has a market cap of 13B. Regarding current trading prices, SRNE is priced at $0.00, while INCY trades at $67.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 336.30. In terms of profitability, SRNE's ROE is -19.05%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SRNE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs UTHR Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, UTHR has a market cap of 12.9B. Regarding current trading prices, SRNE is priced at $0.00, while UTHR trades at $286.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 11.41. In terms of profitability, SRNE's ROE is -19.05%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SRNE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs GMAB Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, GMAB has a market cap of 12.8B. Regarding current trading prices, SRNE is priced at $0.00, while GMAB trades at $20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 12.15. In terms of profitability, SRNE's ROE is -19.05%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SRNE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs KRTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRNE is priced at $0.00, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRNE's ROE is -19.05%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SRNE is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs EXEL Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, SRNE is priced at $0.00, while EXEL trades at $43.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 19.80. In terms of profitability, SRNE's ROE is -19.05%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SRNE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ASND Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ASND has a market cap of 10.6B. Regarding current trading prices, SRNE is priced at $0.00, while ASND trades at $175.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -26.31. In terms of profitability, SRNE's ROE is -19.05%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SRNE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BMRN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, SRNE is priced at $0.00, while BMRN trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 20.03. In terms of profitability, SRNE's ROE is -19.05%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SRNE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MRNA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MRNA has a market cap of 9.9B. Regarding current trading prices, SRNE is priced at $0.00, while MRNA trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -2.94. In terms of profitability, SRNE's ROE is -19.05%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SRNE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RXDX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRNE is priced at $0.00, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRNE's ROE is -19.05%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRNE is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs IMGN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRNE is priced at $0.00, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRNE's ROE is -19.05%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, SRNE is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BPMC Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, SRNE is priced at $0.00, while BPMC trades at $128.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.16. In terms of profitability, SRNE's ROE is -19.05%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SRNE is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs VRNA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, VRNA has a market cap of 8.2B. Regarding current trading prices, SRNE is priced at $0.00, while VRNA trades at $97.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -48.52. In terms of profitability, SRNE's ROE is -19.05%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SRNE is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CERE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRNE is priced at $0.00, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRNE's ROE is -19.05%, compared to CERE's ROE of -0.43%. Regarding short-term risk, SRNE is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BBIO Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BBIO has a market cap of 8B. Regarding current trading prices, SRNE is priced at $0.00, while BBIO trades at $42.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -11.85. In terms of profitability, SRNE's ROE is -19.05%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SRNE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CORT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, SRNE is priced at $0.00, while CORT trades at $74.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 64.65. In terms of profitability, SRNE's ROE is -19.05%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SRNE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ROIVW Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, SRNE is priced at $0.00, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SRNE's ROE is -19.05%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, SRNE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ROIV Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, SRNE is priced at $0.00, while ROIV trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -15.33. In terms of profitability, SRNE's ROE is -19.05%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, SRNE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs TECH Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, TECH has a market cap of 7.7B. Regarding current trading prices, SRNE is priced at $0.00, while TECH trades at $49.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 59.40. In terms of profitability, SRNE's ROE is -19.05%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SRNE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RVMD Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RVMD has a market cap of 7.5B. Regarding current trading prices, SRNE is priced at $0.00, while RVMD trades at $40.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -9.99. In terms of profitability, SRNE's ROE is -19.05%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SRNE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RETA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRNE is priced at $0.00, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRNE's ROE is -19.05%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRNE is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs HALO Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, HALO has a market cap of 6.5B. Regarding current trading prices, SRNE is priced at $0.00, while HALO trades at $52.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 14.05. In terms of profitability, SRNE's ROE is -19.05%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SRNE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs JAZZ Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, SRNE is priced at $0.00, while JAZZ trades at $106.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 14.51. In terms of profitability, SRNE's ROE is -19.05%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SRNE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MDGL Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MDGL has a market cap of 6.3B. Regarding current trading prices, SRNE is priced at $0.00, while MDGL trades at $282.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -15.85. In terms of profitability, SRNE's ROE is -19.05%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SRNE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs IONS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, IONS has a market cap of 6B. Regarding current trading prices, SRNE is priced at $0.00, while IONS trades at $37.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -12.60. In terms of profitability, SRNE's ROE is -19.05%, compared to IONS's ROE of -0.92%. Regarding short-term risk, SRNE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs TGTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, SRNE is priced at $0.00, while TGTX trades at $36.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 146.24. In terms of profitability, SRNE's ROE is -19.05%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SRNE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs TLX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, TLX has a market cap of 5.5B. Regarding current trading prices, SRNE is priced at $0.00, while TLX trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 182.11. In terms of profitability, SRNE's ROE is -19.05%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SRNE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ABCM Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRNE is priced at $0.00, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRNE's ROE is -19.05%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRNE is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ISEE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRNE is priced at $0.00, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRNE's ROE is -19.05%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRNE is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs NUVL Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, SRNE is priced at $0.00, while NUVL trades at $75.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -17.63. In terms of profitability, SRNE's ROE is -19.05%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SRNE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs AMRN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, AMRN has a market cap of 5.2B. Regarding current trading prices, SRNE is priced at $0.00, while AMRN trades at $12.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -2.87. In terms of profitability, SRNE's ROE is -19.05%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, SRNE is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs AXSM Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, SRNE is priced at $0.00, while AXSM trades at $101.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -17.62. In terms of profitability, SRNE's ROE is -19.05%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SRNE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ALKS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, SRNE is priced at $0.00, while ALKS trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 13.93. In terms of profitability, SRNE's ROE is -19.05%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SRNE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ALPN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRNE is priced at $0.00, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRNE's ROE is -19.05%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, SRNE is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs AKRO Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, AKRO has a market cap of 4.3B. Regarding current trading prices, SRNE is priced at $0.00, while AKRO trades at $54.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.41. In terms of profitability, SRNE's ROE is -19.05%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SRNE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs PCVX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, SRNE is priced at $0.00, while PCVX trades at $33.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.33. In terms of profitability, SRNE's ROE is -19.05%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SRNE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ADMA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, SRNE is priced at $0.00, while ADMA trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 21.27. In terms of profitability, SRNE's ROE is -19.05%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SRNE is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs OPT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRNE is priced at $0.00, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRNE's ROE is -19.05%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SRNE and OPT have similar daily volatility (0.00).
SRNE vs MRTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRNE is priced at $0.00, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRNE's ROE is -19.05%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SRNE is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs SLNO Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, SLNO has a market cap of 4.1B. Regarding current trading prices, SRNE is priced at $0.00, while SLNO trades at $81.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -17.18. In terms of profitability, SRNE's ROE is -19.05%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SRNE is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs KRYS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, SRNE is priced at $0.00, while KRYS trades at $138.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 33.11. In terms of profitability, SRNE's ROE is -19.05%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SRNE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ZLAB Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ZLAB has a market cap of 4B. Regarding current trading prices, SRNE is priced at $0.00, while ZLAB trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -14.40. In terms of profitability, SRNE's ROE is -19.05%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, SRNE is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RYTM Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, SRNE is priced at $0.00, while RYTM trades at $62.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -22.19. In terms of profitability, SRNE's ROE is -19.05%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SRNE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CRSP Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CRSP has a market cap of 3.9B. Regarding current trading prices, SRNE is priced at $0.00, while CRSP trades at $45.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -10.15. In terms of profitability, SRNE's ROE is -19.05%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SRNE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MRUS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, SRNE is priced at $0.00, while MRUS trades at $52.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -12.69. In terms of profitability, SRNE's ROE is -19.05%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SRNE is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs PTCT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, SRNE is priced at $0.00, while PTCT trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.62. In terms of profitability, SRNE's ROE is -19.05%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SRNE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CYTK Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CYTK has a market cap of 3.9B. Regarding current trading prices, SRNE is priced at $0.00, while CYTK trades at $32.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.17. In terms of profitability, SRNE's ROE is -19.05%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SRNE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ACAD Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, SRNE is priced at $0.00, while ACAD trades at $22.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 16.41. In terms of profitability, SRNE's ROE is -19.05%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SRNE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RYZB Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRNE is priced at $0.00, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRNE's ROE is -19.05%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRNE is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CBAY Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRNE is priced at $0.00, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRNE's ROE is -19.05%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SRNE is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs SWTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRNE is priced at $0.00, while SWTX trades at $46.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.77. In terms of profitability, SRNE's ROE is -19.05%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SRNE is less volatile compared to SWTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RNA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, SRNE is priced at $0.00, while RNA trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -9.72. In terms of profitability, SRNE's ROE is -19.05%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SRNE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ACLX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, SRNE is priced at $0.00, while ACLX trades at $63.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -21.28. In terms of profitability, SRNE's ROE is -19.05%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SRNE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs RARE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, SRNE is priced at $0.00, while RARE trades at $36.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -6.32. In terms of profitability, SRNE's ROE is -19.05%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SRNE is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs PTGX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, SRNE is priced at $0.00, while PTGX trades at $53.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 68.41. In terms of profitability, SRNE's ROE is -19.05%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SRNE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs AAPG Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, AAPG has a market cap of 3.2B. Regarding current trading prices, SRNE is priced at $0.00, while AAPG trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -49.60. In terms of profitability, SRNE's ROE is -19.05%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SRNE is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs SRRK Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, SRRK has a market cap of 3.2B. Regarding current trading prices, SRNE is priced at $0.00, while SRRK trades at $33.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -13.05. In terms of profitability, SRNE's ROE is -19.05%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SRNE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs LEGN Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, LEGN has a market cap of 3.1B. Regarding current trading prices, SRNE is priced at $0.00, while LEGN trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -28.70. In terms of profitability, SRNE's ROE is -19.05%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SRNE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MTSR Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MTSR has a market cap of 3.1B. Regarding current trading prices, SRNE is priced at $0.00, while MTSR trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -11.43. In terms of profitability, SRNE's ROE is -19.05%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, SRNE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs KYMR Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, SRNE is priced at $0.00, while KYMR trades at $46.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -14.88. In terms of profitability, SRNE's ROE is -19.05%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SRNE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MORF Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SRNE is priced at $0.00, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, SRNE's ROE is -19.05%, compared to MORF's ROE of -0.22%. Regarding short-term risk, SRNE is less volatile compared to MORF. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MOR Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SRNE is priced at $0.00, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, SRNE's ROE is -19.05%, compared to MOR's ROE of +2.51%. Regarding short-term risk, SRNE is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MLTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MLTX has a market cap of 2.8B. Regarding current trading prices, SRNE is priced at $0.00, while MLTX trades at $44.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -19.51. In terms of profitability, SRNE's ROE is -19.05%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, SRNE is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CRNX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, SRNE is priced at $0.00, while CRNX trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.87. In terms of profitability, SRNE's ROE is -19.05%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SRNE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs VKTX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, VKTX has a market cap of 2.8B. Regarding current trading prices, SRNE is priced at $0.00, while VKTX trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -21.43. In terms of profitability, SRNE's ROE is -19.05%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SRNE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs KDNY Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, SRNE is priced at $0.00, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SRNE's ROE is -19.05%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SRNE is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CPRX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, SRNE is priced at $0.00, while CPRX trades at $22.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.10. In terms of profitability, SRNE's ROE is -19.05%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SRNE is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs IMVT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, SRNE is priced at $0.00, while IMVT trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.67. In terms of profitability, SRNE's ROE is -19.05%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, SRNE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MYOV Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, SRNE is priced at $0.00, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SRNE's ROE is -19.05%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SRNE is less volatile compared to MYOV. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs MIRM Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, SRNE is priced at $0.00, while MIRM trades at $50.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -31.24. In terms of profitability, SRNE's ROE is -19.05%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SRNE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs APGE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, APGE has a market cap of 2.5B. Regarding current trading prices, SRNE is priced at $0.00, while APGE trades at $41.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -11.46. In terms of profitability, SRNE's ROE is -19.05%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SRNE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs IBRX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, SRNE is priced at $0.00, while IBRX trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -4.84. In terms of profitability, SRNE's ROE is -19.05%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SRNE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs XENE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, SRNE is priced at $0.00, while XENE trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -9.78. In terms of profitability, SRNE's ROE is -19.05%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SRNE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs PRVB Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, SRNE is priced at $0.00, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SRNE's ROE is -19.05%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SRNE is less volatile compared to PRVB. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs LBPH Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, SRNE is priced at $0.00, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SRNE's ROE is -19.05%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SRNE and LBPH have similar daily volatility (0.00).
SRNE vs DICE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, SRNE is priced at $0.00, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, SRNE's ROE is -19.05%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SRNE is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs LGND Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, SRNE is priced at $0.00, while LGND trades at $114.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -15.77. In terms of profitability, SRNE's ROE is -19.05%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SRNE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs APLS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, SRNE is priced at $0.00, while APLS trades at $17.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -9.79. In terms of profitability, SRNE's ROE is -19.05%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SRNE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CALT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, SRNE's ROE is -19.05%, compared to CALT's ROE of -1.67%. Regarding short-term risk, SRNE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs ARWR Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while ARWR trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -12.51. In terms of profitability, SRNE's ROE is -19.05%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, SRNE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs VCEL Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while VCEL trades at $41.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 836.00. In terms of profitability, SRNE's ROE is -19.05%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SRNE is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs KNSA Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while KNSA trades at $28.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -119.79. In terms of profitability, SRNE's ROE is -19.05%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SRNE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs VCYT Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while VCYT trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 63.60. In terms of profitability, SRNE's ROE is -19.05%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SRNE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BCRX Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BCRX has a market cap of 2.1B. Regarding current trading prices, SRNE is priced at $0.00, while BCRX trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BCRX's P/E ratio is -38.12. In terms of profitability, SRNE's ROE is -19.05%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, SRNE is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs NAMS Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, NAMS has a market cap of 2B. Regarding current trading prices, SRNE is priced at $0.00, while NAMS trades at $18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -9.90. In terms of profitability, SRNE's ROE is -19.05%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, SRNE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs BLTE Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, SRNE is priced at $0.00, while BLTE trades at $61.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -45.22. In terms of profitability, SRNE's ROE is -19.05%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, SRNE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs DNLI Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, DNLI has a market cap of 2B. Regarding current trading prices, SRNE is priced at $0.00, while DNLI trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.10. In terms of profitability, SRNE's ROE is -19.05%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SRNE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs CGON Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, SRNE is priced at $0.00, while CGON trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -17.11. In terms of profitability, SRNE's ROE is -19.05%, compared to CGON's ROE of -0.17%. Regarding short-term risk, SRNE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.
SRNE vs NAMSW Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, NAMSW has a market cap of 1.9B. Regarding current trading prices, SRNE is priced at $0.00, while NAMSW trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SRNE's ROE is -19.05%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, SRNE and NAMSW have similar daily volatility (0.00).
SRNE vs AGIO Comparison
SRNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRNE stands at 1.2M. In comparison, AGIO has a market cap of 1.9B. Regarding current trading prices, SRNE is priced at $0.00, while AGIO trades at $33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRNE currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 2.89. In terms of profitability, SRNE's ROE is -19.05%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, SRNE is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for SRNE.